SPECTRUM: Early global real-world results with aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration

Hani Hasan,[1] Vasileios Konidaris,[2] Clemens Lange,[3,4] Marion R. Munk,[5,6,7] Paolo Lanzetta,[8,9] Varun Chaudhary,[10] Hassiba Oubraham,[11] Tobias Machewitz,[12] Helmut Allmeier,[13] Xin Zhang,[13] Clare Bailey,[14]
on behalf of the SPECTRUM study investigators

[1]Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK; [2]Department of Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK; [3]Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; [4]Department of Ophthalmology, St Franziskus Hospital, Münster, Germany; [5]Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; [6]Department of Ophthalmology, University Hospital Bern, Switzerland; [7]Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; [8]Department of Medicine–Ophthalmology, University of Udine, Udine, Italy; [9]Instituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy; [10]Hamilton Regional Eye Institute, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; [11]Centre OPHTA-45, Montargis, France; [12]Bayer AG, Berlin, Germany; [13]Bayer Consumer Care AG, Basel, Switzerland; [14]Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Presented at the American Society of Retina Specialists 43rd Annual Meeting 2025, Long Beach, CA, USA, July 30 – August 2, 2025

Disclosures

- **Hani Hasan:** Speaker fees and travel grants from AbbVie, Bayer, and Roche
- **VK:** Receives honoraria from AbbVie, Bayer, Novartis, and Roche.
  CL: Receives honoraria from Apellis, Bayer, Biogen, and Novartis.
  MRM: Consulting fees from AbbVie, Allergan, Apellis, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelion, EyePoint, Gensight, Iveric Bio, Isarna Therapeutics, Kubota, Lumithera, Novartis, Ocuterra, Oculis, Ocular Therapeutix, RetinAI, Roche, and Zeiss.
  PL: Consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, EyePoint, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. **VC**: Consulting fees from EyePoint; receives grants from Bayer, Novartis, and Roche; and serves on advisory boards for Alcon, Apellis, Bayer, Boehringer Ingelheim, Novartis, and Roche.
  HO: Consultant for AbbVie, Bayer, Novartis, and Roche. **TM:** Employee of Bayer AG. **HA** and **XZ**: Employees of Bayer Consumer Care AG.
  CB: Received honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche
- The SPECTRUM study (NCT06075147) was sponsored by Bayer Consumer Care AG, Basel, Switzerland
- The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med*. 2022;175:1298–1304)
- Data originally presented at ARVO 2025, Salt Lake City, UT, USA, May 4–8, 2025

SPECTRUM: Global real-world study of aflibercept 8 mg

A **24-month, non-interventional country** and **global cohort** study planned in **18 countries**

2 indications, 4 patient cohorts

Treatment-naïve **nAMD** and previously treated **nAMD**
Treatment-naïve **DME** and previously treated **DME**

Primary endpoint: Change in **VA** from **BL to Month 12**

Secondary endpoints include:

- Change in **VA** and **CRT** from BL to Month 6
- Number of **injections** and **visits**, and **safety** through Month 6

To date, **2896** patients enrolled



BL, baseline; CRT, central retinal thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; VA, visual acuity.

SPECTRUM inclusion criteria

	Population	Diagnosis	Treatment
nAMD cohorts	Aged ≥50 years	A diagnosis of nAMD	Patients across all cohorts had to have been prescribed aflibercept 8 mg as part of routine clinical practice
DME cohorts	Aged ≥18 years with type 1 or type 2 diabetes mellitus	A diagnosis of DME	

All patients were categorized as being either:

Treatment-naïve
Never been exposed to any medical treatment for nAMD/DME

Previously treated
Received prior treatment, including other anti-VEGFs, up to prespecified timepoints before study start

Anti-VEGF, anti-vascular endothelial growth factor.

Enrollment overview

To date, **951** out of **1200 (79%)** planned patients have been enrolled in the **treatment-naïve nAMD** cohort (as of May 30, 2025)



Early outcomes in the first ~100 patients with treatment-naïve nAMD who had a visit and VA assessment at Week 4

Baseline characteristics: Treatment-naïve nAMD

Analysis of patients with a VA assessment at Week 4[a]

Total: 100 patients

Mean age: 79.7 ± 6.6 years

Median (min, max) time from nAMD diagnosis: 0.1 (0.0, 21.9) months

Mean baseline VA: 60.2 ± 17.4 ETDRS letters

Mean baseline CRT: 374 ± 124 µm

Sex



Race[b]



FAS. Percentages may not add up to 100 due to rounding.

[a]Data are mean ± SD unless otherwise indicated. [b]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only.
ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; Max, maximum; Min, minimum; SD, standard deviation; UK, United Kingdom.

Key endpoint: VA through Week 4





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.
CI, confidence interval; OC, observed cases.

CRT through Week 4





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

Proportion of patients without fluid through Week 4



FAS, OC. Values have been rounded to the nearest decimal point.
Based on instructions on the case report form, fluid data were collected during a macular assessment (6 mm) per investigator discretion.

Safety overview: Adverse events

	Total (N=100)
Ocular TEAEs in the study eye, n (%)	3 (3.0)
Non-ocular TEAEs, n (%)	1 (1.0)

No serious ocular or non-ocular TEAEs were reported

Data are from the SAF.
SAF, safety analysis set; TEAE, treatment-emergent adverse event.

Early outcomes in the first ~100 patients with treatment-naïve nAMD who had a visit and VA assessment at Week 8

Baseline characteristics: Treatment-naïve nAMD

Analysis of patients with a VA assessment at Week 8[a]

Total: 114 patients

Mean age: 80.8 ± 7.1 years

Median (min, max) time from nAMD diagnosis: 0.2 (0.0, 21.9) months

Baseline VA: 60.1 ± 17.4 ETDRS letters

Baseline CRT: 358 ± 110 µm

Sex



Race[b]



FAS. Percentages may not add up to 100 due to rounding.

[a]Data are mean ± SD unless otherwise indicated. [b]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only.

Key endpoint: VA through Week 8





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

CRT through Week 8





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

Proportion of patients without fluid through Week 8



FAS, OC. Values have been rounded to the nearest decimal point.
Based on instructions in the case report form, fluid data were collected during a macular assessment (6 mm) per investigator discretion.

Safety overview: Adverse events

	Total (N=114)
Ocular TEAEs in the study eye, n (%)	3 (2.6)
Non-ocular TEAEs, n (%)	5 (4.4)

No serious ocular or non-ocular TEAEs were reported

Data are from the SAF.

Early findings from SPECTRUM support the real-world effectiveness and safety of aflibercept 8 mg in the treatment of treatment-naïve nAMD

More than **2800** patients enrolled in SPECTRUM across **17 countries** to date

More than **900** patients enrolled in the **treatment-naive nAMD cohort** across **13 countries** to date

Early clinical outcomes at Week 4/Week 8

- Improved VA through Week 4 and Week 8 (+2.7 and +3.2 ETDRS letters, respectively) and reduced CRT

Safety outcomes at Week 4/Week 8

- No new safety signals identified
- No cases of IOI or serious ocular TEAEs

As the **first global real-world study of aflibercept 8 mg**, early findings from SPECTRUM will help **inform clinical management** of treatment-naïve nAMD in patients receiving aflibercept 8 mg

Month 6 data will be presented in **2025,** with Month 12 and Month 24 analyses on track

IOI, intraocular inflammation.